Jakmac Tablet contains Tofacitinib 5mg, a Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients. Tofacitinib works by selectively inhibiting JAK enzymes, which play a critical role in the signaling pathways involved in the immune response and inflammation. By modulating these pathways, Jakmac helps reduce joint inflammation, pain, and structural damage associated with autoimmune conditions. The recommended dosage should be determined by a healthcare professional based on the patient's condition and response to therapy. Jakmac is typically administered orally, with or without food, and requires regular monitoring of blood counts, liver function, and lipid profiles due to potential adverse effects such as infections, cytopenias, and elevated liver enzymes. Patients should be screened for tuberculosis and other infections prior to initiating therapy. Caution is advised in individuals with a history of malignancy, chronic infections, or hepatic impairment. Jakmac is contraindicated in patients with hypersensitivity to Tofacitinib or any component of the formulation. It is essential to follow the prescribed regimen and consult a healthcare provider if any side effects or signs of infection occur during treatment.

Dosage & How to Use